GSK extends antibody and RNA deals and boosts OTC portfolio
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has extended its existing deals with BioWa and Prosensa and has acquired certain commercialisation rights to Medivir's OTC cold sore treatment Xerclear (aciclovir plus hydrocortisone).